Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
This share will rise massively soon, this isn’t a ramp. It’s at the leading edge in its field and the price just isn’t right. Remember for the size of Hemo, what they have achieved with the resources they have is truly remarkable.
Just to add Car-T is all the rage and large pharmas are jumping over each other to get in there first. Why would they just ignore Hemo that is at clinical stage and they can get in now for millions instead of billions. It’s coming will just take a bit of time. I’ve been trying to set a con call up with 4 people since Friday and they are busy so imagine trying to get something like this signed off. Prevail may well be ready but the third party if there is one may have said yes ok a week Monday. It’s how business works and remember to them Hemo is a small fish they have bigger ones to fry I’m sure so they wouldn’t just drop everything.
Mr I, there is only so much manipulation you can do. Not you obviously!! But we are at a M/C below 40mil. There is just too much that is so good at Hemo and they are succeeding now all the time. This should re rate very soon. With regards to funding it’s 99.9% certain that they are as JHFH says finalising all the documents. If something was bad and they knew about it? Which they would, it would be market sensitive news and would have to be released. I’m run a large company and it’s not always as easy as saying “ok we are ready can Yiu all be their in the morning” remember the heads of these companies are busy and have other engagements. GL
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group, announces that it has demonstrated in vivo that its proprietary Chimeric Bait Receptor ("CBR") can be delivered intranasally in the form of messenger RNA ("mRNA") for the potential treatment of airborne viral infections.
CBR-based countermeasures against viral infections that are include a novel method of their delivery. To satisfy real-world requirements for the deployment of such countermeasures, they must be both easy to administer and have a long shelf life at ambient temperatures. CBR is a platform technology under development that aims to program the immune cells that are responsible for innate immunity (e.g., macrophages) to eliminate viruses and certain malignant cells.
Our team of scientists has demonstrated in vivo that mRNA encoding a CBR-based therapeutic can be mixed with a polymer and a solvent at room temperature to form polymer nanoparticles encapsulating mRNA. Such nanoparticles can be used to deliver CBR-coding mRNA into the upper respiratory tract ("URT") and lungs of small animals. Once administered, nanoparticles were shown to successfully deliver mRNA into the immune cells of the URT and lungs. The immune cells in turn begin making CBR molecules within hours post-application, potentially becoming active "defenders" against airborne infections.
As previously reported, the Company has been able to dramatically accelerate its research and development efforts by using Artificial Intelligence ("AI") and in-house synthesis of mRNA. AI tools allow the Company's scientists to triage variants of CBR constructs efficiently to select those with the greatest likelihood of success, while in-house mRNA synthesis facilitates the rapid building of CBR constructs.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "This major breakthrough in the method of delivery of our CBR demonstrates that it could potentially be used as an off-the-shelf prevention and/or treatment for viral infections. Intranasal delivery of CBR would be both cost-efficient and easy to administer, making it ideal for the protection of both the civilian population and in biodefense."
hh he only has himself to blame, he knows exactly what he’s doing. he’s probably been advised to stay of x but just cannot help himself. it’s a poor show when investor’s that have put up with a world of ****e over the years are still left guessing. i mean what is the problem with sending and rns out late friday or monday morning detailing the next step’s or even making the vague rns on friday a bit more informative then there would be none of this. people invest their hard earned money in this company and every single time instead of talking about the amazing science we end up talking about vlad’s cryptic tweets. on top of that now he's deleted his account, come on is this the way to act? i’m sure everyone will do well even the poor ****3r5 that got spiked on friday but there are better ways to communicate with investors. aimho.
Copper pot, I am one of the less intelligent and gullible if that’s the case but because of Neil I’ve made thousands of pounds. What’s your point. This share has gone up loads and the only poor sods are the LTH’s. Why not just buy in and get over it. What’s your obsession with trying to drive this down and not up?
Prevail Partners, LLC to invest in Hemogenyx Pharmaceuticals.
· Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023.
So the above extract from the prevail partnership RNS where it says commence in 2023. If this is the case there must be agreed funding in place and this will now just need to be signed. I fully believe anRNS on funding is imminent.